To analyze the prevalence and clinical implications of the eligibility criteria for prolonged dual antithrombotic therapy with ticagrelor 60 mg twice daily and/or rivaroxaban 2.5 mg twice daily in a contemporary real-world ACS registry.
Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry / Cesaro, A; Gragnano, F; Calabrò, P; Moscarella, E; Santelli, F; Fimiani, F; Patti, G; Cavallari, I; Antonucci, E; Cirillo, P; Pignatelli, P; Palareti, G; Pelliccia, F; Bossone, E; Pengo, V; Gresele, P; Marcucci, R. - In: INTERNATIONAL JOURNAL OF CARDIOLOGY. - ISSN 0167-5273. - ELETTRONICO. - 345/2021:(2021), pp. 7-13. [10.1016/j.ijcard.2021.10.138]
Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry
Santelli F;
2021-01-01
Abstract
To analyze the prevalence and clinical implications of the eligibility criteria for prolonged dual antithrombotic therapy with ticagrelor 60 mg twice daily and/or rivaroxaban 2.5 mg twice daily in a contemporary real-world ACS registry.| File | Dimensione | Formato | |
|---|---|---|---|
|
Santelli Prevalence and clinical implications of eligibility criteria for prolonged.pdf
Accesso chiuso
Descrizione: articolo
Tipologia:
Documento in Versione Editoriale
Licenza:
Copyright Editore
Dimensione
1.13 MB
Formato
Adobe PDF
|
1.13 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
|
Santelli+Prevalence+and+clinical+implications+of+eligibility+criteria+for+prolonged-Post_print.pdf
Open Access dal 24/10/2022
Tipologia:
Bozza finale post-referaggio (post-print)
Licenza:
Creative commons
Dimensione
1.55 MB
Formato
Adobe PDF
|
1.55 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
